142 related articles for article (PubMed ID: 22302136)
1. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis.
Wada T; Son Y; Ozaki Y; Nomura S; Iida H
Mod Rheumatol; 2012 Nov; 22(6):824-30. PubMed ID: 22302136
[TBL] [Abstract][Full Text] [Related]
2. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
[TBL] [Abstract][Full Text] [Related]
5. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
van der Heijde D; Klareskog L; Landewé R; Bruyn GA; Cantagrel A; Durez P; Herrero-Beaumont G; Molad Y; Codreanu C; Valentini G; Zahora R; Pedersen R; MacPeek D; Wajdula J; Fatenejad S
Arthritis Rheum; 2007 Dec; 56(12):3928-39. PubMed ID: 18050208
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Martin Mola E; Pedersen R; Robertson D; Chang D; Koenig A; Freundlich B;
Ann Rheum Dis; 2009 Jul; 68(7):1113-8. PubMed ID: 18718986
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L; van der Heijde D; de Jager JP; Gough A; Kalden J; Malaise M; Martín Mola E; Pavelka K; Sany J; Settas L; Wajdula J; Pedersen R; Fatenejad S; Sanda M;
Lancet; 2004 Feb; 363(9410):675-81. PubMed ID: 15001324
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
9. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Genovese MC; Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Cannon GW; Spencer-Green G; Finck BK
Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
[TBL] [Abstract][Full Text] [Related]
10. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Genovese MC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Finck BK
N Engl J Med; 2000 Nov; 343(22):1586-93. PubMed ID: 11096165
[TBL] [Abstract][Full Text] [Related]
11. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
12. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
Genovese MC; Bathon JM; Fleischmann RM; Moreland LW; Martin RW; Whitmore JB; Tsuji WH; Leff JA
J Rheumatol; 2005 Jul; 32(7):1232-42. PubMed ID: 15996057
[TBL] [Abstract][Full Text] [Related]
13. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study.
Kameda H; Kanbe K; Sato E; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Yamanaka H; Takeuchi T
J Rheumatol; 2011 Aug; 38(8):1585-92. PubMed ID: 21572151
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
15. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
Laganà B; Picchianti Diamanti A; Ferlito C; Germano V; Migliore A; Cremona A; Argento G; David V; Salemi S; D'Amelio R
Int J Immunopathol Pharmacol; 2009; 22(2):447-54. PubMed ID: 19505397
[TBL] [Abstract][Full Text] [Related]
16. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
Matsuno H
Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
[TBL] [Abstract][Full Text] [Related]
17. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
van der Kooij SM; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Güler-Yüksel M; Zwinderman AH; Kerstens PJ; van der Lubbe PA; de Beus WM; Grillet BA; Ronday HK; Huizinga TW; Breedveld FC; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2009 Jun; 68(6):914-21. PubMed ID: 18662933
[TBL] [Abstract][Full Text] [Related]
18. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
19. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
[TBL] [Abstract][Full Text] [Related]
20. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
Landewé R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
Arthritis Rheum; 2006 Oct; 54(10):3119-25. PubMed ID: 17009230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
